Cargando…

Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma

BACKGROUND: The immunotherapy with immune checkpoints inhibitors (ICI) has changed the life expectancy in metastatic melanoma (MM) patients. Nevertheless, several patients do not respond hence, the identification and validation of novel biomarkers of response to ICI is of crucial importance. Circula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serratì, Simona, Guida, Michele, Di Fonte, Roberta, De Summa, Simona, Strippoli, Sabino, Iacobazzi, Rosa Maria, Quarta, Alessandra, De Risi, Ivana, Guida, Gabriella, Paradiso, Angelo, Porcelli, Letizia, Azzariti, Amalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764806/ https://www.ncbi.nlm.nih.gov/pubmed/35042524 http://dx.doi.org/10.1186/s12943-021-01490-9

Ejemplares similares

Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma
por: Serratì, Simona, et al.
Publicado: (2023)

uPAR(+) extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients
por: Porcelli, Letizia, et al.
Publicado: (2021)

The ERRα–VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR‐CYP24A1‐ERRα overexpression correlates with poor prognosis in patients with basal‐like breast cancer
por: Danza, Katia, et al.
Publicado: (2021)

Barasertib: a novel approach for the treatment of metastatic melanoma
por: Azzariti, Amalia, et al.
Publicado: (2014)

microRNAs and next generation sequencing for the prognosis of the metastatic melanoma
por: Pinto, Rosamaria, et al.
Publicado: (2015)

The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response
por: Pinto, Rosamaria, et al.
Publicado: (2016)

Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
por: Di Fonte, Roberta, et al.
Publicado: (2023)

Tomatine Displays Antitumor Potential in In Vitro Models of Metastatic Melanoma
por: Serratì, Simona, et al.
Publicado: (2020)

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment
por: Serratì, Simona, et al.
Publicado: (2023)

The β-adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study
por: Porcelli, Letizia, et al.
Publicado: (2020)

Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation
por: Garrisi, Vito Michele, et al.
Publicado: (2014)

Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach
por: De Summa, Simona, et al.
Publicado: (2021)

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
por: Porcelli, Letizia, et al.
Publicado: (2015)

The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015)

CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
por: Porcelli, Letizia, et al.
Publicado: (2019)

The Genetic Germline Background of Single and Multiple Primary Melanomas
por: De Summa, Simona, et al.
Publicado: (2021)

Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study
por: Argentiero, Antonella, et al.
Publicado: (2019)

Behind the Scene: Exploiting MC1R in Skin Cancer Risk and Prevention
por: Manganelli, Michele, et al.
Publicado: (2021)

Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp
por: Quaresmini, Davide, et al.
Publicado: (2021)

The Interaction between Reactive Peritoneal Mesothelial Cells and Tumor Cells via Extracellular Vesicles Facilitates Colorectal Cancer Dissemination
por: Serratì, Simona, et al.
Publicado: (2021)

The mitochondrial master regulator gene PGC1alpha in novel sporadic melanoma cell lines: correlations with BRAF mutational status
por: Guida, Gabriella, et al.
Publicado: (2014)

Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells
por: Azzariti, Amalia, et al.
Publicado: (2019)

Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights
por: Iacobazzi, Rosa Maria, et al.
Publicado: (2021)

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)
por: Guida, Michele, et al.
Publicado: (2018)

Hydroxy-Propil-β-Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models
por: Iacobazzi, Rosa Maria, et al.
Publicado: (2020)

The Role of Non-Coding RNAs as Prognostic Factor, Predictor of Drug Response or Resistance and Pharmacological Targets, in the Cutaneous Squamous Cell Carcinoma
por: Garofoli, Marianna, et al.
Publicado: (2020)

Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm
por: Argentiero, Antonella, et al.
Publicado: (2020)

Genetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a caucasian family
por: De Summa, Simona, et al.
Publicado: (2016)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Salting-Out Approach Is Worthy of Comparison with Ultracentrifugation for Extracellular Vesicle Isolation from Tumor and Healthy Models
por: Serratì, Simona, et al.
Publicado: (2021)

Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position
por: Savino, Salvatore, et al.
Publicado: (2016)

Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma
por: Strippoli, Sabino, et al.
Publicado: (2020)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma
por: Azzariti, Amalia, et al.
Publicado: (2016)

Examining the Relationship between Circulating CD4− CD8− Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy—Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma
por: Strippoli, Sabino, et al.
Publicado: (2021)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
por: Sharma, Meenal, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_miub9vvj3788v96tandnlbcojs